3201, Chapel Hill CRS
Welcome,         Profile    Billing    Logout  
 7 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersen, Susan
NCT06812494: A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Recruiting
2
200
US, RoW
VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg, VRC07-523LS 3200mg, PGT121.414.LS 1600mg, PGDM1400LS 1600mg
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Dale and Betty Bumpers Vaccine Research Center (VRC)
HIV
01/27
09/27
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
CM HIV-Core008, NCT05604209: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART

Active, not recruiting
1
18
US
C62, C1C62, Placebo, Normal saline, Sodium Chloride, M4, M3M4
University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine, HIV-1-infection
09/24
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pedersen, Susan
NCT06812494: A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Recruiting
2
200
US, RoW
VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg, VRC07-523LS 3200mg, PGT121.414.LS 1600mg, PGDM1400LS 1600mg
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Dale and Betty Bumpers Vaccine Research Center (VRC)
HIV
01/27
09/27
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
CM HIV-Core008, NCT05604209: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART

Active, not recruiting
1
18
US
C62, C1C62, Placebo, Normal saline, Sodium Chloride, M4, M3M4
University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine, HIV-1-infection
09/24
02/25

Download Options